# Inari Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inari-medical

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.inarimedical.com
- Total disclosed funding: $44M
- Latest round: Series C (Mar 29, 2018)
- Investors on record: 4

## About

Inari Medical, Inc., based in the US, specializes in developing and commercializing innovative medical devices for treating venous diseases, focusing on advanced solutions for blood clot removal.Inari Medical, Inc. was founded in 2013 in Irvine, US. The company develops medical devices aimed at addressing venous thromboembolism (VTE). It has completed a total of 8 deals, with the most recent deal occurring on March 11, 2022. The firm raised USD 162.00 mn in a Private Placement/Follow-on round. The CEO is Drew Hykes, who leads the company’s strategy and operations.Inari Medical specializes in developing innovative medical devices for treating venous diseases, particularly through endovascular systems for venous thromboembolism (VTE). Key products include the ClotTriever and FlowTriever, which are designed for efficient blood clot removal in hospital settings by interventional radiologists and vascular surgeons. The company markets its solutions across the United States, Europe, and select Asian markets, addressing critical healthcare needs related to deep vein thrombosis and pulmonary embolism.Inari Medical generated revenue of USD 493.63 mn in 2023, with an EBITDA of USD -16.53 mn. The company primarily operates on a B2B model, selling its medical devices directly to hospitals and healthcare providers, and engages in partnerships to ensure access to its treatment solutions.Inari Medical plans to utilize the recent funding of USD 162.00 mn raised in March 2022 to accelerate its commercial, clinical, and technology development programs. The company is focused on expanding its product line and exploring new markets to enhance its presence in the vascular intervention space. Specific upcoming products and their launch dates have not been disclosed, but the strategy aims to increase market penetration in existing regions while assessing opportunities for entry into new geographical markets, thereby broadening its operational footprint.

## Funding rounds

- Series C, Mar 29, 2018, $27M — US Venture Partners, Versant Ventures, Gilde Healthcare
- Series B, Jun 18, 2015, $12M — US Venture Partners, Versant Ventures
- Series A, Oct 16, 2013, $4.7M — US Venture Partners, Versant Ventures, Inceptus Medical

## Investors

- US Venture Partners (https://capitalatlas.ai/funds/us-venture-partners) — Series A, Series B, Series C
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- Inceptus Medical (https://capitalatlas.ai/funds/inceptus-medical) — Series A
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series C